ArticleCancer research2019
Abstract read
In one paragraph
Article in Cancer research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed
3.1field-weighted citation impact, top 8% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 53 citations in OpenAlex.
- HMGA proteins in the nervous system: role in brain tumorigenesis and neurodegeneration.Cell death discovery · 2026Review
- Targeting SRC enhances differentiation and promotes multifaceted cell death mechanisms in recurrent group 3 medulloblastoma.Cell death & disease · 2026Article
- Development and Validation of an LC-MS/MS Method for the Quantitation of JNJ-64619178 (JNJ) in Mouse Plasma: Characterization of In Vitro and In Vivo Pharmacokinetic Properties.Molecules (Basel, Switzerland) · 2026Article
- A tumor-associated photoreceptor signature unifies distinct central nervous system malignancies.Cancer cell · 2026Article
- Decoding the immune microenvironment: precision immunotherapy for medulloblastoma subtypes.Frontiers in immunology · 2026Review
- Investigation of a global mouse methylome atlas reveals subtype-specific copy number alterations in pediatric cancer models.Nature genetics · 2026Article
- Transcriptional regulation of protein synthesis by mediator kinase represents a therapeutic vulnerability in MYC-driven medulloblastoma.Nature communications · 2025Article
- MYC promotes group 3 medulloblastoma cell proliferation and alleviates ROS-induced cell death by upregulating transketolase.Acta neuropathologica communications · 2025Article
- Article
- Medulloblastoma's master regulators and their association with patients' risk.Scientific reports · 2025Article
- OLIG2 mediates a rare targetable stem cell fate transition in sonic hedgehog medulloblastoma.Nature communications · 2025Article
- MYC-dependent upregulation of the de novo serine and glycine synthesis pathway is a targetable metabolic vulnerability in group 3 medulloblastoma.Neuro-oncology · 2025Article
- Arrested development: the dysfunctional life history of medulloblastoma.Genes & development · 2025Review
- ZIC1 is a context-dependent medulloblastoma driver in the rhombic lip.Nature genetics · 2025Article
- DHODH Inhibition SuppressesCancers · 2024Article
- Establishment and Characterization of Three Human Ocular Adnexal Sebaceous Carcinoma Cell Lines.International journal of molecular sciences · 2024Article
- Group 3 medulloblastoma transcriptional networks collapse under domain specific EP300/CBP inhibition.Nature communications · 2024Article
- MYC overexpression and SMARCA4 loss cooperate to drive medulloblastoma formation in mice.Acta neuropathologica communications · 2023Article
- Pediatric Central Nervous System Tumor Overview and Emerging Treatment Considerations.Brain sciences · 2023Review
- Group-specific cellular metabolism in Medulloblastoma.Journal of translational medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 4 institutions in 2 countries.
Ran TaoCenter for Cancer and Immunology, Brain Tumor Institute, Children's National Health System, Washington, DC.
Najiba MuradCenter for Cancer and Immunology, Brain Tumor Institute, Children's National Health System, Washington, DC.
Zhenhua XuCenter for Cancer and Immunology, Brain Tumor Institute, Children's National Health System, Washington, DC.
Peng ZhangDivision of Immunotherapy, Institute of Human Virology, School of Medicine, University of Maryland, College Park, Maryland.ORCID 0000-0003-2598-3544
Konstantin OkonechnikovHopp Children's Cancer Center, NCT, Heidelberg, Germany.
Marcel KoolHopp Children's Cancer Center, NCT, Heidelberg, Germany.
Samuel Rivero-HinojosaCenter for Cancer and Immunology, Brain Tumor Institute, Children's National Health System, Washington, DC.
Christopher LazarskiCenter for Cancer and Immunology, Brain Tumor Institute, Children's National Health System, Washington, DC.
Pan ZhengDivision of Immunotherapy, Institute of Human Virology, School of Medicine, University of Maryland, College Park, Maryland.
Yang LiuDivision of Immunotherapy, Institute of Human Virology, School of Medicine, University of Maryland, College Park, Maryland.
Charles G EberhartDivision of Neuropathology, Johns Hopkins University, Baltimore, Maryland.
Brian R RoodCenter for Cancer and Immunology, Brain Tumor Institute, Children's National Health System, Washington, DC.ORCID 0000-0003-3221-9421
Roger PackerCenter for Cancer and Immunology, Brain Tumor Institute, Children's National Health System, Washington, DC.
Yanxin PeiCenter for Cancer and Immunology, Brain Tumor Institute, Children's National Health System, Washington, DC. ypei@cnmc.org.
Children's National · USUniversity of Maryland, Baltimore · USGerman Cancer Research Center · DEJohns Hopkins University · US
Funding
A Mouse Model to Assess Long Term Immunotherapy-related Adverse Effects in ChildrenR01CA227671 · NCI · UNIVERSITY OF MARYLAND BALTIMORE · PI WANG, YIN · 2018 to 2022
$2.1MThe role of Olig2 in the tumorigenesis, progression and metastasis in MYC-amplified medulloblastomaR01CA241192 · NCI · CHILDREN'S RESEARCH INSTITUTE · PI PEI, YANXIN · 2019 to 2023
$2.0MTumor-initiating and propagating cells in MYC-driven medulloblastomaR21NS102776 · NINDS · CHILDREN'S RESEARCH INSTITUTE · PI PEI, YANXIN · 2017 to 2018
$481k(PQ6) Molecular Mechanisms of Dormancy in MYC-Driven MedulloblastomaR21CA180063 · NCI · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI PEI, YANXIN · 2013 to 2014
$460kNCI NIH HHS R01 CA227671NCI NIH HHS R01 CA241192NCI NIH HHS R21 CA180063NINDS NIH HHS R21 NS102776
Abstract
A subset of group 3 medulloblastoma frequently harbors amplification or overexpression of
Indexed as
AnimalsApoptosisBiomarkers, TumorCell ProliferationCell Transformation, NeoplasticCerebellar NeoplasmsDisease Models, AnimalFormyltetrahydrofolate DehydrogenaseGene Expression ProfilingGene Expression Regulation, NeoplasticHumansMedulloblastomaMiceMice, Inbred C57BLMice, Inbred NODMice, SCIDBiomarkers, TumorFormyltetrahydrofolate DehydrogenaseOxidoreductases Acting on CH-NH Group DonorsProto-Oncogene Proteins c-mycSox2 protein, mouseSOXB1 Transcription Factors
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.